{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:32:21Z","timestamp":1767897141456,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Few real\u2010world studies have reported detailed management and dose adjustment strategies of adverse events (AEs) of ovarian cancer (OC) patients treated with the poly(adenosine diphosphate\u2010ribose) polymerase inhibitor olaparib. This case series aimed to describe olaparib AEs in Chinese OC patients in real\u2010life settings and to explore dose modification strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a detailed examination of the clinical records of OC patients who were treated with olaparib at the Gynecologic Oncology Unit in Hong Kong from September 2015 to December 2019, including baseline characteristics, treatment outcomes, AEs, and management strategies, particularly dose modifications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nineteen patients were included, with a median olaparib treatment duration of 12 (range: 3\u201330) months. For recurrent platinum\u2010sensitive cases (<jats:italic>n<\/jats:italic>\u00a0=\u00a016), the median progression\u2010free survival was 16.0 months (95% confidence interval: 9.5\u201322.5). Eighteen (95%) patients experienced AE(s) of any grade, including four (21%) who experienced grade \u22653 AE(s). The most common AEs were as follows: nonhematologic fatigue (68%), nausea (42%), vomiting (26%), decreased appetite (26%), dyspepsia (21%), dizziness (21%), anemia (37%), neutropenia (26%), and thrombocytopenia (21%). Four specific cases involving anemia, lower limb lymphedema, myeloid neoplasm, and erythema nodosum are discussed separately. Eight patients required dose interruption or reduction due to AEs, of which five patients attempted and tolerated dose re\u2010escalation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, most AEs were mild, but rare AEs were observed. In OC patients, olaparib AE management with dose reductions followed by re\u2010escalations was feasible, including for anemia.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13584","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T19:59:45Z","timestamp":1618603185000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Olaparib dose re\u2010escalation in ovarian cancer patients who experienced severe and\/or uncommon adverse events: A case series"],"prefix":"10.1111","volume":"17","author":[{"given":"Siew\u2010Fei","family":"Ngu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology The University of Hong Kong, Queen Mary Hospital  Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka\u2010Yu","family":"Tse","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology The University of Hong Kong, Queen Mary Hospital  Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy M. Y.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology The University of Hong Kong, Queen Mary Hospital  Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hextan Y. S.","family":"Ngan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology The University of Hong Kong, Queen Mary Hospital  Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen K. L.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology The University of Hong Kong, Queen Mary Hospital  Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"U.S. Food and Drug Administration.FDA approved olaparib (LYNPARZA AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA\u2010mutated (gBRCAm or sBRCAm) advanced epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to first\u2010line platinum\u2010based.https:\/\/www.fda.gov\/drugs\/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients. Accessed January 8 2020."},{"key":"e_1_2_9_3_1","unstructured":"U.S. Food and Drug Administration.FDA approves olaparib for germline BRCA\u2010mutated metastatic breast cancer.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer. Accessed January 8 2020."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.348"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0268"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S169558"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1045875"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70228-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-019-0594-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3106-7"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw133"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S147726"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.06.012"},{"key":"e_1_2_9_16_1","unstructured":"AstraZeneca Hong Kong.Lynparza (olaparib) capsules [pakage insert]. Hong Kong;2018."},{"issue":"15","key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1200\/JCO.2018.36.15_suppl.5548","article-title":"Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum\u2010sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: impact of prior lines of platinum therapy","volume":"36","author":"Korach J","year":"2018","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.06.001"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.10.023"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13104"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.012096"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0024"},{"key":"e_1_2_9_24_1","first-page":"9529821","article-title":"A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer","volume":"2018","author":"Wheelden M","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9512-5"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3484"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71135-0"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0044"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016600"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.60"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091373"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00246"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-7-28"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2016.60217"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-1281-TCFBMR"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.256"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60893-8"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S101333"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13584","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13584","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T21:30:40Z","timestamp":1693603840000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/ajco.13584"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13584","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2021-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}